Premium
Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits?
Author(s) -
Timmers Silvie,
Hesselink Matthijs K.C.,
Schrauwen Patrick
Publication year - 2013
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12185
Subject(s) - resveratrol , sirtuin 1 , sirtuin , type 2 diabetes , obesity , diabetes mellitus , medicine , bioinformatics , pharmacology , biology , endocrinology , biochemistry , acetylation , downregulation and upregulation , gene
The number of people suffering from metabolic disorders is dramatically increasing worldwide. The need for new therapeutic strategies to combat this growing epidemic of metabolic diseases is therefore also increasing. In 2003, resveratrol was discovered to be a small molecule activator of sirtuin 1 (SIRT1), an important molecular target regulating cellular energy metabolism and mitochondrial homeostasis. Rodent studies have clearly demonstrated the potential of resveratrol to improve various metabolic health parameters. To date, however, only limited clinical data are available that have systematically examined the health benefits of resveratrol in metabolically challenged humans. This short review will give an overview of the currently available clinical studies examining the effects of resveratrol on obesity and type 2 diabetes from a human perspective.